Lee's subsidiary gets Chinese rights to Auransa's cardioprotective agent

China Oncology Focus Ltd. received exclusive Chinese rights to preclinical candidate AU018 from AI company Auransa Inc. (Palo Alto, Calif.). China Oncology Focus also gained rights to AU018 in other undisclosed countries in Southeast Asia.

Auransa will receive an undisclosed upfront payment and is eligible for milestones plus high single-digit royalties. The company said it is eligible to receive a total of up to $22.5 million upon achievement of key milestones...